Broadwood Partners, L.p. bought $2.0M of IMDX
owner at Oncocyte Corp. 570,184 shares at an average of $3.56, traded Apr 23, 2026, filed Apr 27, 2026.
Score components
- +12Role10% owner
- +25Trade size$2.0M at market
- 0Relative to holdingsHoldings up 4.7%
- +8Price context58% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +66.9%, 3m +22.4%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000919574-26-002414, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 23, 2026 | POpen-market purchase Common Stock, no par value | +280,381 | $3.50 | $982k | 12,395,081 | Apr 27, 2026 |
| Apr 23, 2026 | POpen-market purchase Common Stock, no par valueindirect: Footnote | +0 | $0.00 | $0 | 12,395,081 | Apr 27, 2026 |
| Apr 24, 2026 | POpen-market purchase Common Stock, no par value | +38,880 | $3.53 | $137k | 12,433,961 | Apr 27, 2026 |
| Apr 24, 2026 | POpen-market purchase Common Stock, no par valueindirect: Footnote | +0 | $0.00 | $0 | 12,433,961 | Apr 27, 2026 |
| Apr 27, 2026 | POpen-market purchase Common Stock, no par value | +250,923 | $3.64 | $913k | 12,684,884 | Apr 27, 2026 |
| Apr 27, 2026 | POpen-market purchase Common Stock, no par valueindirect: Footnote | +0 | $0.00 | $0 | 12,684,884 | Apr 27, 2026 |
Related signals
Other insiders at Oncocyte Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | IMDXbuy Oncocyte Corp | Broadwood Partners, L.p. owner | $653k 182,861 shares | +2% | |
| 32Weak | IMDXbuy Oncocyte Corp | Broadwood Partners, L.p. owner | $3.0M 521,739 shares | +5% | |
| 57Moderate | Oncocyte Corp | Andrea S. James Chief Financial Officer | $200k 97,561 shares | +182% | |
| 50Moderate | Oncocyte Corp | Broadwood Partners, L.p. owner | $11M 5,165,695 shares | +83% | |
| 30Weak | Oncocyte Corp | Patrick W Smith owner | $192k 90,219 shares | +5% | |
| 31Weak | Oncocyte Corp | Andrew Arno director | $26k 12,500 shares | +18% | |
| 38Weak | IMDXbuy Oncocyte Corp | Andrea S. James Chief Financial Officer | $46k 20,000 shares | +59% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.